Nuvation Bio (NUVB) shares were up more than 13% in recent Tuesday trading after the company said it has enrolled the first patient in its phase 3 trial of Ibtrozi for the treatment of early-stage non-small cell lung cancer.

The phase 3 study will enroll about 180 patients in the US, Canada, Europe, Japan and China with resected ROS1-positive early-stage non-small cell lung cancer who have undergone surgery.

The primary completion date of the study is estimated to be in 2033, the company said.

Price: 3.66, Change: +0.44, Percent Change: +13.51